22 August 2018 - Renflexis has been added to drug formulary for the treatment of adult and paediatric Crohn's disease and ulcerative colitis, as well as for the treatment of fistulising Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults.
Merck Canada today announced that the province of British Columbia will now reimburse Renflexis (infliximab for injection) under its public drug plan effective August 21, 2018.
Renflexis (infliximab for injection) is approved for the treatment of Crohn's disease and ulcerative colitis in adult and pediatric patients, as well as fistulising Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis in adults.